Regentis Biomaterials (NYSEAMERICAN:RGNT) Trading Down 3.3% – What’s Next?

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT)’s share price dropped 3.3% during mid-day trading on Wednesday . The stock traded as low as $2.21 and last traded at $2.37. Approximately 25,655 shares changed hands during mid-day trading, an increase of 265% from the average daily volume of 7,036 shares. The stock had previously closed at $2.45.

Analyst Ratings Changes

Separately, ThinkEquity upgraded shares of Regentis Biomaterials to a “strong-buy” rating in a report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Strong Buy”.

Regentis Biomaterials Trading Down 3.3%

The business’s fifty day moving average price is $3.16.

Institutional Investors Weigh In On Regentis Biomaterials

An institutional investor recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC acquired a new stake in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned approximately 5.79% of Regentis Biomaterials at the end of the most recent reporting period.

Regentis Biomaterials Company Profile

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.